'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply
- PMID: 35798145
- PMCID: PMC9250883
- DOI: 10.1016/j.cmi.2022.06.028
'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply
Comment on
-
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM.Clin Microbiol Infect. 2022 Nov;28(11):1519. doi: 10.1016/j.cmi.2022.06.013. Epub 2022 Jun 20. Clin Microbiol Infect. 2022. PMID: 35738319 Free PMC article. No abstract available.
References
-
- Klopfenstein T., Gendrin V., Zayet S. Re: 'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study’ by Broman et al. Clin Microbiol Infect. 2022 [Epub ahead of print] - PMC - PubMed
-
- Broman N., Feuth T., Vuorinen T., Valtonen M., Hohenthal U., Löyttyniemi E., et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clin Microbiol Infect. 2022;28:844–851. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
